FDA approves first treatment for certain types of poor-prognosis AML

4 August 2017
jazzpharma_big

The US Food and Drug Administration has approved Vyxeos (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of acute myeloid leukemia (AML), a rapidly progressing and life-threatening blood cancer.

Vyxeos, from Ireland-incorporated Jazz Pharmaceuticals (Nasdaq: JAZZ), is indicated for the treatment of adults with newly-diagnosed t-AML or myelodysplasia-related changes (AML-MRC).

News of the approval, which comes around a month earlier than expected, sent Jazz’s shares up 2.66% to $154.41 by close of trading on Thursday. Vyxeos will be commercially available within a week. RBC Capital Markets’ analysts forecasts peak sales of $235 million in 2022.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical